BeOne Medicines Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.
BeOne Medicines reported results from its HERIZON-GEA-01 Phase 3 trial, showing median overall survival of 27.0 months for TEVIMBRA plus ZIIHERA and chemotherapy, with a hazard ratio of 0.65. ZIIHERA plus chemotherapy alone showed 22.9 months. The trial met a primary endpoint with a p-value of 0.0088. The study involved 914 patients across 30 countries, with no new safety signals identified.
BeOne Medicines presented data from its solid tumor pipeline at ESMO 2026, including updates on GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and PRMT5 inhibitor. The company also shared evidence for TEVIMBRA in lung and gastrointestinal cancers, including a combination with ZIIHERA in HER2+ gastroesophageal adenocarcinoma. BeOne aims to advance these therapies toward pivotal development.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BEIGF (BeOne Medicines Ltd.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent BEIGF coverage spans financial news, insider activity and regulation.
In the last 30 days, BEIGF insiders filed 16 SEC Form 4 transactions — no purchases and 16 sales ($22.6M). The most active reporter was Wang Xiaodong with 15 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.
BeOne Medicines reported results from its HERIZON-GEA-01 Phase 3 trial, showing median overall survival of 27.0 months for TEVIMBRA plus ZIIHERA and chemotherapy, with a hazard ratio of 0.65. ZIIHERA plus chemotherapy alone showed 22.9 months. The trial met a primary endpoint with a p-value of 0.0088. The study involved 914 patients across 30 countries, with no new safety signals identified.
BeOne Medicines presented data from its solid tumor pipeline at ESMO 2026, including updates on GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and PRMT5 inhibitor. The company also shared evidence for TEVIMBRA in lung and gastrointestinal cancers, including a combination with ZIIHERA in HER2+ gastroesophageal adenocarcinoma. BeOne aims to advance these therapies toward pivotal development.
Jefferies analysts highlighted Oncorus (ONC), Revolution Medicines (RVMD), and Alnylam Pharmaceuticals (ALNY) as top mid-cap biotech stocks ahead of earnings. ONC received a $410 price target, RVMD is expected to exceed revenue estimates, and ALNY's target was lowered to $250. The firm cited specific catalysts and data for each company.
Wang Xiaodong sold 31,027 shares of BeOne Medicines Ltd. (ONC) at an average of $350.99 ($349.56–$353.24, $10.89M total) across 5 trades on 2026-10-13 under a Rule 10b5-1 trading plan.
AlphAI scores every news story that mentions BEIGF with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.
2 min readBeOne Medicines reported results from its HERIZON-GEA-01 Phase 3 trial, showing median overall survival of 27.0 months for TEVIMBRA plus ZIIHERA and chemotherapy, with a hazard ratio of 0.65. ZIIHERA plus chemotherapy alone showed 22.9 months. The trial met a primary endpoint with a p-value of 0.0088. The study involved 914 patients across 30 countries, with no new safety signals identified.
2 min readBeOne Medicines presented data from its solid tumor pipeline at ESMO 2026, including updates on GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and PRMT5 inhibitor. The company also shared evidence for TEVIMBRA in lung and gastrointestinal cancers, including a combination with ZIIHERA in HER2+ gastroesophageal adenocarcinoma. BeOne aims to advance these therapies toward pivotal development.
2 min readJefferies analysts highlighted Oncorus (ONC), Revolution Medicines (RVMD), and Alnylam Pharmaceuticals (ALNY) as top mid-cap biotech stocks ahead of earnings. ONC received a $410 price target, RVMD is expected to exceed revenue estimates, and ALNY's target was lowered to $250. The firm cited specific catalysts and data for each company.
2 min readWang Xiaodong sold 31,027 shares of BeOne Medicines Ltd. (ONC) at an average of $350.99 ($349.56–$353.24, $10.89M total) across 5 trades on 2026-10-13 under a Rule 10b5-1 trading plan.
1 min readBeOne Medicines Ltd.'s Scientific Advisory Board Chair Xiaodong Wang sold 31,028 American Depositary Shares (ADS) under a Rule 10b5-1 plan, according to a filing. He exercised options for 403,364 Ordinary Shares at $2.84 each, acquiring the ADS. Each ADS represents 13 Ordinary Shares. Wang reported direct holdings of 4,588,113 Ordinary Shares and options covering 806,715 Ordinary Shares post-transaction.
1 min readWang Xiaodong sold 31,028 shares of BeOne Medicines Ltd. (ONC) at an average of $364.79 ($356.97–$367.23, $11.32M total) across 10 trades on 2026-09-28 under a Rule 10b5-1 trading plan.
1 min readBeOne Medicines Ltd. (ONC) officer Chan Lee proposed selling 1,115 ADS worth $407,276, with the sale expected on September 30, 2026. The shares were acquired through restricted stock unit vesting between July 2022 and June 2025. Morgan Stanley Smith Barney LLC is the broker for the transaction.
1 min readWang Xiaodong sold 38,287 shares of BeOne Medicines Ltd. (ONC) at an average of $349.10 ($345.38–$351.25, $13.37M total) across 8 trades on 2026-09-08 under a Rule 10b5-1 trading plan.
1 min readBeOne Medicines (ONC) agreed with the U.S. government to exempt its pharmaceuticals from Section 232 tariffs in exchange for pricing commitments and $1B+ U.S. manufacturing investments, including a $300M expansion in New Jersey. The deal reduces tariff risk but may lower future product pricing.
2 min read
